Skip to main content
. Author manuscript; available in PMC: 2015 May 20.
Published in final edited form as: Oncogene. 2013 Nov 18;33(47):5457–5466. doi: 10.1038/onc.2013.486

Fig. 5. Inhibiting the ERK1/2 pathway affects KIF2C gene expression more than KIF2A.

Fig. 5

RNA was isolated from (A) HBEC3KT, (B) HBEC3KT53 and (C) HBEC3KTRL53 treated for 48 hr with 1 µM PD0325901 followed by qPCR measure of KIF2C gene expression. Three different experiments were analyzed by an unpaired t-test resulting in p-value (A) 0.0045 (B) 0.0028 (C) < 0.0001. RNA was isolated from (D) HBEC3KT, (E) HBEC3KT53, or (F) HBEC3KTRL53 and KIF2A gene expression was measured by qPCR after 48 hrs of treatment with PD0325901. Data from three experiments was graphed. Statistical analysis was performed by t-test of control versus treatment: p-value (D) 0.0533, (E) 0.4795 and (F) 0.0301. Treatment of (G) HBEC3KT, (H) HBEC3KT53 and (I) HBEC3KTRL53 with 10 µM LY294002 followed by qPCR for KIF2C gene expression as above. Statistical analysis was performed by t-test of control versus treatment: p-value (G) 0.1464, (H) 0.0192 and (I) 0.0628.